Background: The reported risk of coronary heart disease (CHD) in patients with a history of kidney stones is conflicting.
Aims: The objective of this meta-analysis was to assess the association between a history of kidney stones and CHD risk.
Materials And Methods: A literature search was performed using MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews from inception until April 04, 2014. Studies that reported odds ratios or hazard ratios comparing the risk of CHD in patients with a history of kidney stones versus those without a history of kidney stones were included. Pooled risk ratios (RRs) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse variance method.
Results: Seven study populations from four cohort studies and one cross-sectional study were identified and included in the data analysis. The pooled risk ratio (RR) of CHD in patients with kidney stones was 1.24 (95% CI, 1.10-1.40). This result remained significant (RR, 1.23 [95% CI, 1.08-1.41]) when the sensitivity analysis was restricted to only cohort studies. A history of kidney stones was associated with increased CHD risk in females (RR, 1.43 [95% CI, 1.12-1.82]), whereas the association was not significant in males (RR, 1.14 [95% CI, 0.94-1.38]).
Conclusions: Our study demonstrates a statistically significant increased risk of CHD in female patients with prior kidney stones. This finding suggests that a history of kidney stones is a risk factor for CHD in females and may impact clinical management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264294 | PMC |
| http://dx.doi.org/10.4103/1947-2714.145477 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolic dysfunction associated steatotic liver and kidney stones: what is going on?
Curr Opin Nephrol Hypertens
January 2025
Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Purpose Of Review: Metabolic dysfunction associated steatotic liver disease (MASLD) is increasing throughout the world, affecting nearly one in three individuals. Kidney stone disease, which is also increasing, is associated with MASLD. Common risk factors for both, including obesity, diabetes, dyslipidemia, hypertension, and metabolic syndrome, are likely drivers of this association.
View Article and Find Full Text PDFThe role of renal dual-energy computed tomography in exploring the gouty kidney: the RENODECT study.
Ann Med
December 2025
Department of Medical Imaging, Lille Catholic University, Saint-Philibert Hospital, ETHICS laboratory, Lille, EA, France.
Objective: The objective of this study was to explore the ability of dual-energy computed tomography (DECT) to detect monosodium urate (MSU) crystal deposits in the kidneys and renal artery walls, and uric acid urolithiasis, in patients with gout and chronic kidney disease (CKD).
Methods: Patients with gout and with stage 2-4 CKD were prospectively included in this cross-sectional study. Patients underwent renal, knee and feet DECT scans.
Exploring the links between gallstone disease, non-alcoholic fatty liver disease, and kidney stones: A path to comprehensive prevention.
World J Gastroenterol
January 2025
Université de Bourgogne, Institut Agro-INRAe, Dijon 21000, France.
The recent study exploring the bidirectional associations between gallstone disease, non-alcoholic fatty liver disease, and kidney stone disease highlights a critical concern in chronic disease management. Given the rising global prevalence of these conditions, understanding their interconnections is essential. The study emphasizes the importance of shared risk factors, such as obesity, type 2 diabetes, dyslipidemia, and oxidative stress, and calls for multidisciplinary screening strategies.
View Article and Find Full Text PDFWhich combination of medical expulsive therapy is more effective for treatment of distal ureteral stone in adults? A systematic review and network meta-analysis.
BMC Urol
January 2025
Urology and Nephrology Research Center (UNRC), Research Institute for Urology and Nephrology, Center of Excellence in Urology, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
Background: Medical Expulsive Therapy (MET) has been recommended as an established modality for the treatment of distal ureteral stones due to its clearance rate, pain control, and patient satisfaction while having minimal morbidity in comparison to other urologic interventions. In some studies, a combination of medications has been used, which we assessed in this network meta-analysis (NMA).
Methods: We conducted systematic searches in PubMed, Scopus, and Web of Science to identify relevant trials published between 2001 and 2024.
Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8).
Pediatr Nephrol
January 2025
Novo Nordisk A/S, Lexington, MA, USA.
Background: Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder with dysregulated glyoxylate metabolism in the liver. Oxalate over-production leads to renal stones, progressive kidney damage and renal failure, with potentially life-threatening systemic oxalosis. Nedosiran is a synthetic RNA interference therapy, designed to reduce hepatic lactate dehydrogenase (LDH) to decrease oxalate burden in PH.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!